ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WITH STEM CELL QUALITIES

具有干细胞特性的新型人类 CD8 记忆细胞亚群的分析

基本信息

项目摘要

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area 04, Clinical Research and specific Challenge Topic 04-AI-102 - The human immune response to infection and immunization - Profiling via modern immunologic methods and systems biology. The development and maintenance of memory T cells is a hallmark of the host response to acute and persistent viral infections and a major objective of vaccination for infectious diseases and cancer. Analysis of the phenotype and function of memory T cells in both mice and humans has identified two broad subsets of long-lived memory cells termed central memory (TCM), defined by expression of CD45O and CD62L; and effector memory (TEM), defined by expression of CD45RO and the absence of CD62L. Recent work in the applicant's lab has identified a subset of quiescent memory CD8+ T cells in normal individuals that express cell surface markers that enable their separation from the more prevalent TCM and TEM subsets, and includes molecules shared by hematopoietic stem cells. These quiescent memory T cells exhibit higher ATP binding cassette (ABC) transporter activity, rapidly efflux fluorescent dyes and chemotherapy drugs and are resistant to cytotoxic chemotherapy in vitro and in vivo compared with the majority of memory T cells. The high-effluxing T cells have a diverse T cell receptor repertoire, contain T cells specific for persistent and acute viruses, and contribute to repopulation of memory T cells in individuals who have received chemotherapy. Preliminary gene expression arrays performed on sort-purified subpopulations of memory and na¿ve T cells demonstrate that the subsets of memory T cells with high efflux capacity have a distinct transcriptional profile compared with the majority of TM cells, and with TN cells. The studies in this challenge grant will deliver a detailed database on the frequency, functional properties and gene expression profile of these novel subsets of human antigen experienced T cells, and elucidate their development after vaccination. The potential impact of this work relates to improving our understanding of the mechanisms responsible for the durability of human CD8+ T memory in normal individuals and those undergoing chemotherapy or vaccination. The studies have implications for elucidating the nature of protective immunity that might be elicited by vaccines for infectious diseases and cancer, and could provide a marker for the integrity of host immunity to pathogens in aging. The specific aims are: Aim 1. To compare the frequency, transcriptional profile and factors governing maintenance and differentiation of chemotherapy resistant IL-18R?hi CD161hi subsets of human memory CD8+ T cells with IL-18Rlo CD161lo subsets of TCM and TEM, and with TN. The proposed studies will determine the frequency of CMhi and EMhi in normal adult humans (age 18-80), determine the transcriptional profile of these subsets in ten donors, and compare the functional properties of CMhi and EMhi with the respective non-effluxing subsets and with TN. Aim 2. To determine if primary or booster vaccination of humans with vaccinia virus induces a longlived subset of vaccinia virus-specific CD8+ CMhi and EMhi T cells. The time after infection or vaccination when this novel subset of IL18R?hi CD161hi virus-specific T cells might develop has not been defined. The proposed studies will examine the presence of vaccinia virus specific T cells in individuals with remote vaccinia immunization, recent vaccinia boosting and in vaccinia na¿ve individuals receiving a primary vaccination. PUBLIC HEALTH RELEVANCE: The development and maintenance of memory T cells is a hallmark of the host response to acute and persistent viral infections and a major objective of vaccination for infectious diseases and cancer. Progress in defining the qualitative attributes of memory T cells that contribute to their longevity has been much less significant, particularly in humans. Addressing these issues requires a greater understanding of the subsets of T cells that make up the human memory T cell pool and the application of novel approaches to interrogate the cellular and molecular programs that maintain these cells. The studies in this challenge grant will determine the frequency, functional properties and gene expression profile of novel subsets of human memory T cells that have characteristics of long-lived cells, and elucidate their development after vaccination. The potential impact of this work relates to improving our understanding of the mechanisms responsible for the durability of human CD8+ T memory in normal individuals and those undergoing chemotherapy or vaccination.
描述(由申请人提供):本申请涉及广泛的挑战领域 04、临床研究和特定挑战主题 04-AI-102 - 人体对感染和免疫的免疫反应 - 通过现代免疫学方法和系统生物学进行分析。 记忆 T 细胞的发育和维持是宿主对急性和持续性病毒感染反应的标志,也是传染病和癌症疫苗接种的主要目标。对小鼠和人类记忆 T 细胞的表型和功能的分析已确定。长寿命记忆细胞的两大子集,称为中枢记忆(TCM),由CD45O和CD62L的表达定义;以及效应记忆(TEM),由CD45RO的表达和CD62L的缺失定义。实验室在正常个体中发现了一个静态记忆 CD8+ T 细胞子集,这些细胞表达细胞表面标记,使其能够与更常见的 TCM 和 TEM 子集分离,并且包括造血干细胞共享的分子,这些静态记忆 T 细胞表现出更高的 ATP 结合能力。与大多数记忆T细胞相比,高流出T细胞具有盒式(ABC)转运蛋白活性、快速流出荧光染料和化疗药物并且在体外和体内对细胞毒性化疗具有抵抗力。 T 细胞受体库包含针对持久性和急性病毒的 T 细胞,有助于接受化疗的个体中记忆 T 细胞的重新增殖。 ve T 细胞表明,与大多数 TM 细胞和 TN 细胞相比,具有高流出能力的记忆 T 细胞亚群具有独特的转录特征。本次挑战资助的研究将提供有关频率、功能特性的详细数据库。和这些新的人类抗原经历T细胞亚群的基因表达谱,并阐明它们在疫苗接种后的发育。这项工作的潜在影响涉及提高我们对正常个体和那些人的人类CD8+ T记忆持久性机制的理解。正在接受化疗或这些研究对于阐明传染病和癌症疫苗可能引起的保护性免疫的性质具有重要意义,并且可以为衰老过程中宿主对病原体免疫的完整性提供标记。比较人类记忆 CD8+ T 细胞的化疗耐药性 IL-18R?hi CD161hi 亚群与 TCM 和 TEM 的 IL-18Rlo CD161lo 亚群的频率、转录谱和控制维持和分化的因素,以及拟议的研究将确定正常成年人(18-80 岁)中 CMhi 和 EMhi 的频率,确定十个供体中这些子集的转录谱,并将 CMhi 和 EMhi 的功能特性与各自的非供体进行比较。目标 2. 确定人类痘苗病毒的初次或加强疫苗接种是否会诱导痘苗病毒特异性 CD8+ CMhi 和 EMhi 的长寿亚群。 T 细胞。感染或接种疫苗后,这种新的 IL18R?hi CD161hi 病毒特异性 T 细胞亚群可能发育的时间尚未确定。拟议的研究将检查远程痘苗免疫的个体中是否存在痘苗病毒特异性 T 细胞。最近的痘苗加强和痘苗 na¿ ve 个人接受初级疫苗接种。 公共卫生相关性:记忆 T 细胞的发育和维持是宿主对急性和持续性病毒感染反应的标志,也是传染病和癌症疫苗接种的主要目标。它们的寿命要低得多,特别是在人类中,解决这些问题需要更好地了解构成人类记忆 T 细胞库的 T 细胞亚群,并应用新方法来探究维持这些细胞和分子程序。细胞中的研究。这项挑战资助将确定具有长寿细胞特征的新型人类记忆 T 细胞亚群的频率、功能特性和基因表达谱,并阐明它们在疫苗接种后的发育。 这项工作的潜在影响涉及提高我们对正常个体和接受化疗或疫苗接种的人 CD8+ T 记忆持久性机制的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STANLEY R. RIDDELL其他文献

STANLEY R. RIDDELL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STANLEY R. RIDDELL', 18)}}的其他基金

Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
  • 批准号:
    10700908
  • 财政年份:
    2019
  • 资助金额:
    $ 47.97万
  • 项目类别:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
  • 批准号:
    10601293
  • 财政年份:
    2019
  • 资助金额:
    $ 47.97万
  • 项目类别:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
  • 批准号:
    10174871
  • 财政年份:
    2019
  • 资助金额:
    $ 47.97万
  • 项目类别:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
  • 批准号:
    10436174
  • 财政年份:
    2019
  • 资助金额:
    $ 47.97万
  • 项目类别:
Targeting Alloreactivity for Leukemia Eradication
针对白血病根除的同种异体反应性
  • 批准号:
    8277822
  • 财政年份:
    2011
  • 资助金额:
    $ 47.97万
  • 项目类别:
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES
增强 T 细胞克隆过继转移的策略
  • 批准号:
    8357607
  • 财政年份:
    2011
  • 资助金额:
    $ 47.97万
  • 项目类别:
Targeted immunotherapy of breast cancer with central memory T cells
中央记忆T细胞对乳腺癌的靶向免疫治疗
  • 批准号:
    8181485
  • 财政年份:
    2010
  • 资助金额:
    $ 47.97万
  • 项目类别:
EVALUATING THE ENGINEERING OF CYTOMEGALOVIRUS-SPECIFIC CD8+ T CELL CLONES
评估巨细胞病毒特异性 CD8 T 细胞克隆的工程设计
  • 批准号:
    8172786
  • 财政年份:
    2010
  • 资助金额:
    $ 47.97万
  • 项目类别:
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES
增强 T 细胞克隆过继转移的策略
  • 批准号:
    8172773
  • 财政年份:
    2010
  • 资助金额:
    $ 47.97万
  • 项目类别:
ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WITH STEM CELL QUALITIES
具有干细胞特性的新型人类 CD8 记忆细胞亚群的分析
  • 批准号:
    7937922
  • 财政年份:
    2009
  • 资助金额:
    $ 47.97万
  • 项目类别:

相似国自然基金

基于超声多模态评价技术探讨肝脏靶向递送ABCA1新策略在动脉粥样硬化防治中的应用
  • 批准号:
    81871357
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
基于SIRT1-LXR通路的化合物E4023抗动脉粥样硬化的作用及机制研究
  • 批准号:
    81703503
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
基于LXRα-SREBP1-ABCA1/G1信号通路的益气活血化痰方调脂抗动脉粥样硬化机制研究
  • 批准号:
    81774088
  • 批准年份:
    2017
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
肝脏X受体激动剂干预β淀粉样蛋白诱导的视网膜炎性反应的作用及机制
  • 批准号:
    81670881
  • 批准年份:
    2016
  • 资助金额:
    51.0 万元
  • 项目类别:
    面上项目
新型ABCA1上调剂E17241改善糖脂代谢紊乱的机制研究
  • 批准号:
    81573482
  • 批准年份:
    2015
  • 资助金额:
    50.0 万元
  • 项目类别:
    面上项目

相似海外基金

Nonlipogenic ABCA1 inducers for ADRD
ADRD 的非脂肪生成 ABCA1 诱导剂
  • 批准号:
    10418342
  • 财政年份:
    2022
  • 资助金额:
    $ 47.97万
  • 项目类别:
Nonlipogenic ABCA1 inducers for ADRD
ADRD 的非脂肪生成 ABCA1 诱导剂
  • 批准号:
    10651799
  • 财政年份:
    2022
  • 资助金额:
    $ 47.97万
  • 项目类别:
Control of Neutrophilic Inflammation in Intestinal Health and Disease
控制肠道健康和疾病中的中性粒细胞炎症
  • 批准号:
    10671690
  • 财政年份:
    2016
  • 资助金额:
    $ 47.97万
  • 项目类别:
Control of Neutrophilic Inflammation in Intestinal Health and Disease
控制肠道健康和疾病中的中性粒细胞炎症
  • 批准号:
    10454910
  • 财政年份:
    2016
  • 资助金额:
    $ 47.97万
  • 项目类别:
Control of Neutrophilic Inflammation in Intestinal Health and Disease
控制肠道健康和疾病中的中性粒细胞炎症
  • 批准号:
    10263264
  • 财政年份:
    2016
  • 资助金额:
    $ 47.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了